Gapping up
In reaction earnings/guidance:
- CWH +26.3%, HLF +17.3%, IPHI +12.5%, SPWR +12.1%, VECO +10.8%, UI +9.9%, TWNK +8.7%, GH +8.4%, LSI +8.3%, PEB +8.3%, CARG +8.3%, SKYW +8.3%, FLY +8.3%, CNDT +7.8%, UBER +7.6%, QRVO +7.1%, HSC +6.8%, AAXN +6.7%, NBL +6.3%, PBYI +6.1%, SAIL +6.1%, SVMK +5.9%, CVA +5.6%, ITGR +5.5%, GPRO +5.3%, KTOS +4.9%, ING +4.8%, AL +4.5%, DBX +4.4%, PRDO +4.4%, FLEX +4.1%, ARNA +4.1%, MTG +3.9%, TEN +3.8%, PBA +3.6%, HASI +3.4%, CWST +3%, KIM +2.9%, XRAY +2.8%, OCUL +2.7%, CARR +2.4%, BR +2.3%, EXC +2.2%, BRX +1.8%, GLUU +1.8%, MTW +1.7%, LYV +1.6%, RGNX +1.3%, BLMN +1.2%, FSLR +1.1%, TSM +1.1% (April sales)
Other news:
- PSTI +22.3% (FDA clears Pluristem's IND application for phase II COVID-19 study)
- RDHL +11.6% (receives FDA approval for IND application for a Phase 2a clinical study evaluating its investigational drug, opaganib in patients with confirmed moderate-to-severe SARS-CoV-2 infection)
- FDP +4.2% (reinstates share repurchase program)
- OMI +1.5% (files for $300 mln mixed securities shelf offering)
- F +1.3% (outlines phased production and operations resumption)
Analyst comments:
- CPSI +3.8% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- TAST +2.3% (upgraded to Buy from Hold at Craig Hallum)
- LBTYA +1.5% (upgraded to Buy from Neutral at New Street)
- HAIN +1.1% (upgraded to Neutral from Underweight at JP Morgan)